Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the FXR-agonist EYP001a in Chronically HBV Infected Subjects
NCT03272009 is registered in ClinicalTrials.gov with Enyo Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the FXR-agonist EYP001a in Chronically HBV Infected Subjects
- Lead sponsor
- Enyo Pharma
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 21, 2017
- Completion date
- July 30, 2018
- Enrollment
- 73 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.